Will Novartis' Earnings Impress Wall Street?
Shares of Swiss pharmaceutical giant Novartis are up more than 16% since the start of 2013, and its total return this year has been only slightly better than the broader market. The company is set to release its second-quarter results tomorrow, and this will be a major catalyst for the stock --- but how will this drugmaker fare? Which business segments should investors focus on, and what are the key areas to watch when the results are available? Health care analyst Macaluso discusses these topics in the following video and focuses on three main areas.
One of the most attractive parts of owning a pharmaceutical stock like Novartis is its dividend, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
The article Will Novartis' Earnings Impress Wall Street? originally appeared on Fool.com.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
